4-[5-(5-Acetyl-2-propoxyphenyl)-3-ethyl-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl]butanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[5-(5-Acetyl-2-propoxyphenyl)-3-ethyl-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl]butanoic acid
• 英文别名: 4-[5-(5-acetyl-2-propoxyphenyl)-3-ethyl-7-oxo-6H-pyrazolo[4,3-d]pyrimidin-2-yl]butanoic acid
• 化学式: C₂₂H₂₆N₄O₅
• 分子量: 426.472
• InChiKey: HHIWYPJIOQKDPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Pharmaceutically active compounds
  申请人：——

  公开号：US20020198223A1

  公开（公告）日：2002-12-26

  Compounds of general formula I: 1 or pharmaceutically or veterinarily acceptable salts, solvates, polymorphs or pro-drugs thereof wherein: wherein R 1 , R 2 , R 3 , R 4 , X and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.

  通式I：1的化合物：其中R1，R2，R3，R4，X和A具有所述含义，其为治疗和预防需要抑制环状鸟苷酸3'，5'-一磷酸酯酶（例如cGMP PDE5）的医疗情况有用的药用或兽医可接受的盐，溶剂化合物，多晶体或前药。
• PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1372656A1

  公开（公告）日：2004-01-02
• US6784185B2
  申请人：——

  公开号：US6784185B2

  公开（公告）日：2004-08-31
• [EN] PYRAZOLO`4,3-D.PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS<br/>[FR] COMPOSES PYRAZOLO[4,3-D]PYRIMIDINONE EN TANT QU'INHIBITEURS DE GMPC PDE
  申请人：PFIZER LTD

  公开号：WO2002074312A1

  公开（公告）日：2002-09-26

  Compounds of general formula (I), or pharmaceutically or veterinarily acceptable salts, solvates, polymorphs or pro-drugs thereof wherein: wherein R?1, R2, R3, R4¿, X and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.